The activation of NF-κB in breast cancer has been extensively described in oestrogen receptor negative (ER−) breast tumours and ER− breast cancer cell lines suggesting an important inhibitory crosstalk between both signalling pathways (Biswas et al, 2000, 2001, 2004; Zhou et al, 2005). The gene discussed is NFKB1; the disease is breast carcinoma.